Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
921-940 of 1,694 trials

Advanced NSCLC: NVL-520 Treatment Study

We are testing a new medication, NVL-520, for patients with advanced ROS1-positive solid tumors, including non-small cell lung cancer. The study aims to find the best dose and evaluate its effectiveness and safety.

Advanced ROS1-positive Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Danicopan for Pediatric PNH Patients

We are studying whether adding danicopan to existing treatments helps children with Paroxysmal Nocturnal Hemoglobinuria improve their hemoglobin levels and quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyPediatrics

Fecal Microbiota Transplantation for Crohn’s Disease After Anti-TNF Withdrawal

We are studying whether fecal microbiota transplantation can help maintain remission in Crohn’s disease patients after stopping anti-TNF treatment. This trial compares FMT to a sham procedure to assess its effectiveness in preventing relapse and improving gut health.

Crohn's DiseaseConfirmation phase (III)Monitoring phase (IV)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Duchenne Muscular Dystrophy: Givinostat Study for Young Boys

We are studying the safety and effects of givinostat in boys aged 2 to under 6 years with Duchenne Muscular Dystrophy. This trial aims to understand how the drug works in their bodies and its impact on muscle function.

Duchenne Muscular DystrophyEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Type 2 Diabetes: Dapansutrile Study

We are testing a new oral medication for people with type 2 diabetes to see if it helps lower blood sugar levels better than a placebo. The study also looks at its safety and effects on insulin function.

Type 2 Diabetes6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDiabetologyEndocrinology

Relapsed Multiple Myeloma: Daratumumab Treatment Study

We are comparing two treatment strategies using Daratumumab, Lenalidomide, and Dexamethasone for patients with relapsed multiple myeloma. The goal is to see if a fixed treatment duration is as effective as continuous therapy.

Myeloma Recurrence>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Baricitinib for Calcium Pyrophosphate Disease

We are studying whether Baricitinib can reduce inflammation and improve symptoms in people with calcium pyrophosphate dihydrate deposition disease. This trial will help us understand its effects on pain and inflammation.

Calcium Pyrophosphate Deposition Disease3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Type 1 Diabetes: Metformin's Impact on Arterial Health

We are studying whether metformin can slow down artery calcification and improve blood flow in people with type 1 diabetes who do not have chronic kidney disease. This research may help us understand how to better manage cardiovascular risks in these patients.

Vascular CalcificationType 1 Diabetes>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyEndocrinologyInternal Medicine

Antisynthetase Syndrome: Cyclophosphamide vs Tacrolimus

We are comparing the effects of Cyclophosphamide and Azathioprine against Tacrolimus in patients with antisynthetase syndrome-related lung disease. The goal is to see which treatment better improves lung function and quality of life.

Interstitial Lung DiseaseConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

Fecal Microbiota Transfer for Diabetes Control After Bariatric Surgery

We are studying whether fecal microbiota transfer can help improve blood sugar levels in patients who had bariatric surgery and are in diabetes remission. This trial will explore its effects on insulin production and overall health.

Type 2 Diabetes>2 yearsConfirmation phase (III)Investigational MedicinesEndocrinologyInternal Medicine

Prurigo Nodularis: Povorcitinib Treatment Study

We are studying the effects of povorcitinib on itching and skin lesions in people with prurigo nodularis. The goal is to see if it improves symptoms and quality of life while ensuring safety.

Prurigo Nodularis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

COPD Exacerbation: New Diagnostic Strategy

We are testing a new method using advanced diagnostics to see if it can help reduce antibiotic use during severe COPD flare-ups. This study compares this approach to standard treatment to evaluate its effectiveness and safety.

Severe COPD with Ventilation Support>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPulmonology

Dermatomyositis: Baricitinib Treatment Study

We are studying whether baricitinib can help patients with dermatomyositis improve without using steroids. This trial compares its effects to a placebo while providing usual care.

Dermatomyositis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesDermatologyRheumatology

Acromegaly: Paltusotine Treatment Study

We are studying the long-term safety and effectiveness of paltusotine for people with acromegaly. This research aims to improve treatment options for managing this condition.

Acromegaly>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

Carcinoid Syndrome: Paltusotine Treatment Study

We are evaluating the safety and how the body processes different doses of paltusotine in people with carcinoid syndrome. This study aims to ensure the treatment is safe and well-tolerated.

Carcinoid Syndrome3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Painful Venous Malformations: Apixaban Study

We are investigating whether apixaban can help reduce pain and improve quality of life for patients with painful venous malformations. The study also looks at safety and how the medication affects blood clotting.

Venous Malformation1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Diffuse Cutaneous Systemic Sclerosis: Ianalumab Study

We are testing a new medication, ianalumab, for people with diffuse cutaneous systemic sclerosis. The goal is to see if it improves symptoms and lung function compared to a placebo.

Systemic Scleroderma>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Postoperative Pain Relief After Hip Surgery: Intrathecal Morphine Study

We are testing whether intrathecal morphine, with or without a specific nerve block, can improve pain relief after total hip arthroplasty. This study aims to find the best way to manage pain during recovery.

Total Hip Replacement Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Cardiovascular Risk Management: BIO-RISK-EVENT Study

We are testing a new approach to managing heart health in patients at high risk for heart events. The goal is to see if this intensified treatment is more effective than standard care.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Dapagliflozin for Decompensated Liver Cirrhosis

We are studying whether dapagliflozin is safe and effective for patients with decompensated liver cirrhosis compared to standard treatments. The trial also looks at how it may affect quality of life and various health markers.

Decompensated Liver Cirrhosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine